Test Price
4,600 AED✅ Home Collection Available
Cancer 50 Gene Panel (NGS) Test in UAE | Precision Oncology Molecular Profiling
Executive Summary & Core Metrics
- ✓Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- ✓Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection for blood specimens (Available daily from 8 AM to 11 PM); Secure Medical Courier Solid Tissue Specimen Retrieval for FFPE blocks.
- ✓Clinical Guidance: Telephonic Post-Test Genetic Counselling – expert interpretation of your molecular results.
- ✓Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Cancer 50 Gene Panel (NGS) Test employs next-generation sequencing to simultaneously analyze 50 clinically relevant genes implicated in hereditary and somatic cancers, providing actionable insights for targeted therapy selection, prognosis, and familial risk stratification. Backed by ISO-certified laboratory protocols and strict DHA compliance, results are delivered within 10 working days with physician-level post-test guidance.
This test is performed on either peripheral blood (EDTA) for hematologic malignancies or formalin-fixed paraffin-embedded (FFPE) tumour tissue for solid neoplasms. The comprehensive NGS platform detects single nucleotide variants, small insertions and deletions, and copy number alterations across the curated gene panel.
| Feature | Our Test – Cancer 50 Gene Panel NGS | Closest Alternative (Single-Gene PCR) |
|---|---|---|
| Precision & Scope | 50-gene targeted NGS with derived variant allele frequency | Limited to 1–3 mutations; high risk of missing co-mutations |
| Methodology | Next-Generation Sequencing (NGS), ISO 9001:2015 compliant | Allele-specific PCR, non-ISO |
| Turnaround Time | 10 working days | 7–21 days, variable |
| Clinical Utility | Comprehensive actionable report for oncologists | Fragmented information; requires multiple tests |
Physician Insight & Safety Protocols
"As a diagnostic radiologist specializing in oncologic imaging and tissue characterization, I view this NGS panel as a critical complement to histopathology and radiological staging. The 50-gene profile reveals mutational drivers that inform targeted therapy selection and hereditary risk assessment. However, molecular findings must always be correlated with full clinicoradiological context. Our multidisciplinary team ensures every result is interpreted within your complete clinical picture."
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology | DHA Registration ID: 61713011
Medication Advisory
Do not discontinue any prescribed medication, including anticoagulants or targeted therapies, without consulting your referring physician. This genetic test does not replace ongoing medical management.
Exclusion Criteria & Emergency Red Flags
- Not suitable for individuals under 18 years without verifiable parental or legal guardian consent in accordance with UAE federal healthcare regulations.
- FFPE tissue block must contain at least 10% tumour nuclei; samples with insufficient tumour cellularity will be cancelled and recollection arranged.
- Improperly fixed specimens or those exposed to extreme temperature fluctuations during transport will be rejected for processing.
- Emergency Warning:
- If you experience severe pain, uncontrolled bleeding, respiratory distress, or acute neurological deterioration, seek immediate emergency medical care. This test is a molecular profiling tool and is never a substitute for urgent clinical evaluation.
Patient FAQ & Clinical Guidance
1. Who should consider taking the Cancer 50 Gene Panel (NGS) Test?
Individuals with a personal or family history of cancer seeking targeted therapy guidance and hereditary risk assessment. This test is recommended for oncology patients requiring molecular profiling for treatment decisions, and for asymptomatic individuals with a strong familial cancer pattern who wish to understand their genetic susceptibility. Your referring oncologist will determine if this panel is appropriate for your specific clinical scenario.
2. How is the sample collected and what are the requirements?
Collection follows a precise protocol depending on the specimen type: For hematologic malignancies, 3 mL of peripheral blood is drawn into a lavender-top EDTA tube, shipped under refrigerated conditions (2–8°C) and never frozen. For solid tumours, an FFPE tissue block cut at 4–5 µm sections with at least 10% tumour content is required, shipped at ambient temperature via secure medical courier. A completed NGS Test Requisition Form (Form 40) must accompany every specimen. VIP mobile phlebotomy for blood draws is available daily from 8 AM to 11 PM across Dubai.
3. What can I expect after the test and will my insurance cover it?
You will receive a comprehensive molecular report within 10 working days, with optional telephonic genetic counselling included at no extra charge. The report details actionable mutations, associated drug sensitivities, and risk stratification. Insurance coverage varies by policy; our team provides direct billing verification via WhatsApp at +971 54 548 8731 prior to collection. All genetic data is handled in full compliance with UAE federal data protection laws.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
This service fully adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, stored within DHA-approved facilities, and processed under strict confidentiality protocols. The laboratory holds ISO 9001:2015 accreditation (Cert: INT/EGQ/2509DA/3139). Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | Cancer 50 Gene Panel (NGS) Test |
| Price (AED) | 4,600 |
| Turnaround Time | 10 Working Days |
| Sample Type / Matrix | Peripheral Blood (EDTA) for hematologic malignancies; FFPE Tumour Tissue Block for solid neoplasms |
| Methodology Used | Next-Generation Sequencing (NGS) – Targeted Gene Panel |
| ICD-10-CM Code | Z12.89 (Encounter for screening for malignant neoplasm of other sites) / C80.1 (Malignant neoplasm without specification of site) |
| LOINC Code | 91847-2 (DNA mutations detected in Blood or Tissue by Sequencing) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians